Command Palette

Search for a command to run...

Preprint WatchModerateSeptember 1st, 2026

Multiple mechanisms regulate the nanoscale organization of PD-L1 at the cell surface

Franken, G. A.; Arp, A. B.; Cerina, D.; van Esch, V. M. R.; Scheijen, B.; van Spriel, A. B.

PD-L1 is organised into nanoscale surface clusters regulated by cortical actin, galectin-3 and membrane cholesterol, and cluster architecture governs PD-1 binding and T cell inhibition.

Moderate contradiction

2 prior failures

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

The claim here is that PD-L1 potency depends on nanoscale spatial organisation rather than expression level alone, which if correct would explain part of why PD-L1 expression predicts response so poorly. The Claidex graph holds two CD274 failures pointing in different directions. Incyte discontinued its oral small-molecule PD-L1 inhibitor in solid tumours for strategic reasons (incb099280-cd274-oral-pd-l1-solid-tumors-phase1-strategic-discontinuation), and avelumab with lenvatinib failed on efficacy in pediatric high-grade CNS tumours (avelumab-lenvatinib-cd274-pediatric-cns-tumors-phase1-efficacy-failure). The cluster-architecture model is most consequential for the small-molecule route, since agents that dimerise and internalise PD-L1 act on exactly the spatial variable this work describes. Programs citing this mechanism should show that a cluster-level readout predicts T cell reactivation in primary human tumour material before it is used to select patients.

Abstract excerpt

The immune checkpoint protein PD-L1 plays a pivotal role in tumor immune evasion by binding to PD-1 on immune cells, including T lymphocytes. While the expression and function of PD-L1 have been well studied, the importance of its spatial organization on the cell surface of tumor cells remains poorly understood. In this study, we used super-resolution microscopy combined with biochemical perturbations to investigate the factors regulating PD-L1 clustering and its effects on PD-1 binding and T cell inhibition. We found that PD-L1 is organized into nanoscale clusters at the plasma membrane, with distinct regulatory roles for the actin cytoskeleton, galectin-3, and cholesterol. Disruption of cortical actin increased PD-L1 cluster size, while galectin-3 promoted smaller, denser clusters and increased PD-L1 lateral mobility. Cholesterol depletion reduced PD-L1 cluster size and number and impaired PD-1 binding. These findings indicate that PD-L1 surface organization is collectively regulated by the actin cytoskeleton, galectin-3, and membrane cholesterol within the plasma membrane of tumour cells. Our results provide new insights into the dynamic regulation of PD-L1 and its potential as a therapeutic target in cancer immunotherapy.

Matching Claidex post-mortems

2 of 2 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.